The Clinical Significance of Serum VEGF,bFGF and TNF-α in Non-small Cell Lung Cancer
LI Ying,DONG Liang,LI Hai-jin,et al. (Shaoxing Hospital,China Medical University,Shaoxing 312030,China)
[Purpose] To investigate the levels of serous vascular endothelial growth factor (VEGF),basic fibroblast growth factor (bFGF),and tumor necrosis factor-α (TNF-α) in patients with non-small cell lung cancer(NSCLC) and their relationships with clinical characteristics,and their clinical significance in the evaluation of treatment outcomes were studied. [Methods] The levels of serous VEGF,bFGF and TNF-α were detected by enzyme-linked immunosorbent assay (ELISA) in NSCLC patients before chemotherapy and one week after chemotherapy. [Results] Serous VEGF,bFGF and TNF-α before chemotherapy were correlated with clinical stage (P 0.05),but not with age,gender and pathological type. Among 68 patients with advance NSCLC, the levels of serous VEGF,bFGF and TNF-α declined significantly after chemotherapy in clinical benefit patients than those in patients with progressive disease (PD) (P0.05). [Conclusion] Serous VEGF,bFGF and TNF-α are related to the cancer load in NSCLC patients. Serous VEGF,bFGF and TNF-α might be helpful in predicting of chemotherapeutic response.